Parkinson's Disease


$100 per visit


Parkinson’s Disease (APL-130277)

Official Title

Parkinson's Disease

Study Summary

A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 18-100
Inclusion Diagnosed with Parkinson's Disease and on a stable dose of Carbidopa/Levodopa at least 4 times a day or Rytary 3 times a day.
Exclusion Atypical or secondary parkinsonism.
Start Date
Compensation $100 per visit
Location Orlando, FL

Study Information

Condition Parkinson's Disease
Study Phase Phase 3

Administrative Information

Investigators Ira J Goodman, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.